With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren’t shocked by the setback.
John Lechleiter told local leaders Friday morning that while community engagement might not immediately impact the bottom line, it can be beneficial to a company’s ongoing mission.
Pharmaceutical company stocks were among the winners in early trading Wednesday as Republicans’ sweeping election victory eased concerns that Democrats would enact controls on drug prices. Eli Lilly and Co. shares jumped 4 percent.
The company's top-selling product, the insulin Humalog, saw U.S. sales by volume rise 10 percent in the third quarter. But because of rebates and other discounts, revenue dropped 14 percent.
Makers of insulin became the latest target for Sen. Bernie Sanders, who has been going after pharmaceutical companies one by one over the issue of high U.S. drug prices.
Drugmakers including Eli Lilly and Co. are becoming increasingly vocal in fighting a California ballot proposition designed to bring down prices on prescription medicine.
Sales of Lilly's Humalog insulin, its top-selling product, fell 9 percent, to $641 million, offsetting gains by a stable of new drugs that is helping the company weather a blitz of patent expirations.
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
Eli Lilly and Co. is pledging $90 million over five years to improve access to treatment for diabetes, cancer and tuberculosis in developing countries—the latest push in its philanthropic strategy of building health care systems around the world and increasing the market for its prescription drugs.
The residents who sued sought to revoke the school’s property-tax exemption, in part because Princeton shares commercial royalties with faculty from a patent that Indianapolis-based Eli Lilly and Co. turned into the cancer drug Alimta.
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
Pharma giant Novo Nordisk announced Thursday that it is cutting 1,000 jobs after slashing forecasts for 2016, citing lower prices for diabetes drugs. Novo and competitors such as Indianapolis-based Eli Lilly will likely have to keep tightening their belts as prices and profit margins fall, experts say.
On Jan. 1, Dave Ricks becomes CEO of drugmaker Eli Lilly and Co. as it tries to launch new products after a tough stretch of patent expirations. To prepare, Ricks has spent a lot of time with outgoing CEO John Lechleiter “learning from the master.”
Drugmakers facing a price war in the diabetes market, including Indianapolis-based Eli Lilly and Co., are betting on new technologies to withstand the competition.
Eli Lilly and Co. and its partner cannot stop competitors from selling generic versions of testosterone treatment Axiron, a federal judge in Indianapolis has ruled.
Named AZD3293, the drug belongs to a novel class of drugs that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
